Mike Doustdar: Inside Novo Nordisk’s Bold New Era of Leadership

Summary

Maziar “Mike” Doustdar’s rise at Novo Nordisk is a classic internal success story: from a junior administrative role in 1992 to President and CEO on 7 August 2025. He built his career running international operations, overseeing around DKK 112 billion in global sales in 2024 and earning DKK 57.1 million that year.

Doustdar’s early actions as CEO signal a sharper, more aggressive strategy. He pushed a near-$10 billion offer for Metsera to secure a 50% stake and bolster Novo’s obesity pipeline. At the same time, Novo is navigating tougher market dynamics — fierce competition from Eli Lilly, pricing pressures, and a pared-back 2025 outlook — prompting large-scale restructuring and job cuts to prioritise R&D, M&A and speed to market.

Key Points

Doustdar joined Novo Nordisk in 1992 and became CEO on 7 August 2025, after decades of international roles.
As head of international operations he oversaw roughly DKK 112 billion in 2024 sales, giving him deep market experience.
Reported total compensation for 2024 was DKK 57.1 million, down from DKK 68.2 million in 2023 due to reduced short-term incentives.
He has shown a willingness to take big risks, advancing a nearly $10bn offer for Metsera to strengthen Novo’s obesity drug pipeline.
Novo faces intense competition and has cut its 2025 profit and sales outlook amid pricing pressure in the GLP-1 market.
Doustdar is implementing large-scale job cuts and structural changes to free resources for innovation and M&A.
His leadership marks a shift from cautious stewardship to an offensive, high-stakes growth strategy in a competitive therapeutic area.

Context and relevance

This profile matters because Novo Nordisk is a central player in the global obesity and diabetes markets. Doustdar’s approach — aggressive M&A, operational streamlining and a readiness to confront competitors — will influence pricing, R&D priorities and consolidation across the sector. Investors, industry watchers and healthcare policymakers should watch how these moves affect market share, drug access and long-term innovation.

Why should I read this?

Short version: if you care about pharma, investing or jobs in healthcare, this is where the action is. Novo’s new CEO is swapping caution for big bets — that can mean major upside or messy disruption. Read this to get the headlines fast and understand why the next 18 months could reshape the obesity-drug landscape.

Author style

Punchy: this piece cuts straight to why Doustdar’s promotion matters. It’s not just a human-interest rise story — it foreshadows strategic shifts that will ripple through pharma markets. If you want the detail, dig in; if you want the gist, this summary gives you it in a minute.